National Pharmaceutical Pricing Authority Nppa
- All
- News
- Videos
-
Remdesivir Prices Cut On Government Intervention: Industry Body
To enhance the availability of remdesivir injection, used in the treatment of COVID-19, pharmaceutical companies have reduced the price following the government's intervention, the National Pharmaceutical Pricing Authority (NPPA) said on Saturday.
-
Fortis Hospital Charged Adya's Parents 1,208 Per Cent More For Syringes: NPPA
The Fortis Memorial hospital in Gurgaon charged 1,208 per cent more than procurement price for much of the medical equipment, including disposable syringes, to the parents of seven-year-old dengue patient Adya who had died at the hospital despite undergoing treatment for two weeks.
-
Fortis Dengue Case: Drug Pricing Body Seeks Bill Copies From Hospital
The National Pharmaceutical Pricing Authority (NPPA) asked Fortis Healthcare to provide copies of bills in relation to the case of alleged overcharging of a dengue patient by its hospital in Gurugram.
-
Drug-Pricing Regulator Wants Medical Devices Added To Price Control List
The National Pharmaceutical Pricing Authority (NPPA) had said it did not plan further measures after prices of some heart stents were cut in February by 75 percent
-
Prices of Cancer and Diabetes Drugs Are Slashed Down by 86%
In a series of tweets, the National Pharmaceutical Pricing Authority or NPPA on Monday announced just how the authority has come to the rescue of all those spending thousands.
-
Cancer Drug Prices Slashed Up To 86% In A Year: Regulator
The other pharma players the prices whose cancer medicines have been reduced are Natco Pharma and Emcure pharmaceuticals among others, it added.
-
Merck Gets Demand Notice From Regulator
Merck said the government has issued the demand notice despite the fact that the company was neither a manufacturer nor a marketer of the subject drug.
-
Drug Pricing Regulator To Soon Fix Ceiling Rates Of Stents
The Department of Pharmaceuticals has in a notification put bare metal stents and drug eluting stents (DES) in the Schedule I of DPCO 2013.
-
Regulator Approves Norms For Discontinuation Of Scheduled Drugs
To ensure availability of essential drugs in the market, the National Pharmaceutical Pricing Authority (NPPA) is putting in place a framework for alternative arrangements in case of discontinuation of scheduled formulations by private pharmaceutical firms, among other measures.
-
Government To Amend Norms For Fixing Prices Of 350 Drugs In 15 Days
Drugs Prices Control Order will be amended in the next 15 days to enable the regulator NPPA to fix prices of about 350 medicines whose market data is not available, Union Minister Ananth Kumar said on Monday.
-
Notices Issued To 263 Pharma Firms For Overcharging In FY16
The National Pharmaceutical Pricing Authority (NPPA) has issued notices to 263 firms that were found overcharging during 2015-16, Parliament was informed on Tuesday.
-
Drug Price Controller Fixes Price Of 70 Drug Formulation Packs
Last month, NPPA had fixed the ceiling price of as many as 103 drug formulation packs, including those used for treating HIV/AIDS, bacterial infections, tuberculosis, high blood pressure, epilepsy, Hepatitis C and diabetes.
-
Prices of 103 Formulation Packs to Get Cheaper
With the NPPA's move, some of the key drugs such as Tenofovir, Lamivudine, Raltegravir used for treatment of HIV/AIDS and Sofosbuvir, which is used against Hepatitis C will become cheaper.
-
Drug Price Cut Yielded Rs 2,772-Cr Benefit to Public: Government
Out of a total of 680 under the National List of Essential Medicines (NLEM) under the scheduled category of DPCO, 2013, the National Pharmaceutical pricing Authority (NPPA) has already fixed the ceiling prices in respect of 530 medicines, Minister of State of Chemicals and Fertilizers Hansraj Gangaram Ahir said in a reply to a question in the Lok S...
-
Regulator Exempts Wockhardt's 3 Insulin Products From Price Control
Drug regulator National Pharmaceutical Pricing Authority (NPPA) has exempted Wockhardt's three insulin products from price controls for a period of five years with effect from January 8 this year.
-
Remdesivir Prices Cut On Government Intervention: Industry Body
To enhance the availability of remdesivir injection, used in the treatment of COVID-19, pharmaceutical companies have reduced the price following the government's intervention, the National Pharmaceutical Pricing Authority (NPPA) said on Saturday.
-
Fortis Hospital Charged Adya's Parents 1,208 Per Cent More For Syringes: NPPA
The Fortis Memorial hospital in Gurgaon charged 1,208 per cent more than procurement price for much of the medical equipment, including disposable syringes, to the parents of seven-year-old dengue patient Adya who had died at the hospital despite undergoing treatment for two weeks.
-
Fortis Dengue Case: Drug Pricing Body Seeks Bill Copies From Hospital
The National Pharmaceutical Pricing Authority (NPPA) asked Fortis Healthcare to provide copies of bills in relation to the case of alleged overcharging of a dengue patient by its hospital in Gurugram.
-
Drug-Pricing Regulator Wants Medical Devices Added To Price Control List
The National Pharmaceutical Pricing Authority (NPPA) had said it did not plan further measures after prices of some heart stents were cut in February by 75 percent
-
Prices of Cancer and Diabetes Drugs Are Slashed Down by 86%
In a series of tweets, the National Pharmaceutical Pricing Authority or NPPA on Monday announced just how the authority has come to the rescue of all those spending thousands.
-
Cancer Drug Prices Slashed Up To 86% In A Year: Regulator
The other pharma players the prices whose cancer medicines have been reduced are Natco Pharma and Emcure pharmaceuticals among others, it added.
-
Merck Gets Demand Notice From Regulator
Merck said the government has issued the demand notice despite the fact that the company was neither a manufacturer nor a marketer of the subject drug.
-
Drug Pricing Regulator To Soon Fix Ceiling Rates Of Stents
The Department of Pharmaceuticals has in a notification put bare metal stents and drug eluting stents (DES) in the Schedule I of DPCO 2013.
-
Regulator Approves Norms For Discontinuation Of Scheduled Drugs
To ensure availability of essential drugs in the market, the National Pharmaceutical Pricing Authority (NPPA) is putting in place a framework for alternative arrangements in case of discontinuation of scheduled formulations by private pharmaceutical firms, among other measures.
-
Government To Amend Norms For Fixing Prices Of 350 Drugs In 15 Days
Drugs Prices Control Order will be amended in the next 15 days to enable the regulator NPPA to fix prices of about 350 medicines whose market data is not available, Union Minister Ananth Kumar said on Monday.
-
Notices Issued To 263 Pharma Firms For Overcharging In FY16
The National Pharmaceutical Pricing Authority (NPPA) has issued notices to 263 firms that were found overcharging during 2015-16, Parliament was informed on Tuesday.
-
Drug Price Controller Fixes Price Of 70 Drug Formulation Packs
Last month, NPPA had fixed the ceiling price of as many as 103 drug formulation packs, including those used for treating HIV/AIDS, bacterial infections, tuberculosis, high blood pressure, epilepsy, Hepatitis C and diabetes.
-
Prices of 103 Formulation Packs to Get Cheaper
With the NPPA's move, some of the key drugs such as Tenofovir, Lamivudine, Raltegravir used for treatment of HIV/AIDS and Sofosbuvir, which is used against Hepatitis C will become cheaper.
-
Drug Price Cut Yielded Rs 2,772-Cr Benefit to Public: Government
Out of a total of 680 under the National List of Essential Medicines (NLEM) under the scheduled category of DPCO, 2013, the National Pharmaceutical pricing Authority (NPPA) has already fixed the ceiling prices in respect of 530 medicines, Minister of State of Chemicals and Fertilizers Hansraj Gangaram Ahir said in a reply to a question in the Lok S...
-
Regulator Exempts Wockhardt's 3 Insulin Products From Price Control
Drug regulator National Pharmaceutical Pricing Authority (NPPA) has exempted Wockhardt's three insulin products from price controls for a period of five years with effect from January 8 this year.
